Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12928288 | 0.75 | CYP1A2 (0.34) | RAB9A | |
| SCHEMBL17664058 | 0.72 | KMT2A (0.37) | KMT2AALDH1A1 | |
| SCHEMBL14754408 | 0.69 | KDM4E (0.42) | SLC6A2SLC6A3SLC6A4KDM1A | |
| SCHEMBL19049033 | 0.68 | DRD2 (0.37) | — | |
| SCHEMBL28909423 | 0.68 | MECP2 (0.33) | LMNACYP2A6HTR3A | |
| SCHEMBL21202765 | 0.68 | LPL (0.42) | — | |
| SCHEMBL17179136 | 0.66 | HTR2C (0.42) | LMNASLC6A3MEN1KMT2ASLC6A4 | |
| SCHEMBL10231026 | 0.66 | ALDH1A1 (0.46) | LMNACYP2A6HTR3APRCPSLC6A2 | |
| SCHEMBL3966012 | 0.62 | SLC6A2 (0.42) | LMNACYP2A6HTR3APRCPSLC6A2 | |
| SCHEMBL27818765 | 0.62 | LMNA (0.38) | LMNACYP2A6HTR3APRCPSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | LMNA 594/4885CYP2A6 2170/4885HTR3A 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.